SPOTLIGHT: Toyama seeks early flu pact
Japan's Toyama Chemical is looking to do a development and marketing rights deal on a promising, early-stage bird flu therapy in order to gin up some revenue. Any pact prior to proof-of-concept is likely to go at a discount. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
